Sexual Disorders and Quality of Life in Parkinson’s Disease

Claudia Marques Santa Rosa Malcher, MD,1 Kleber Roberto da Silva Gonçalves Oliveira, MD,2 Milena Coelho Fernandes Caldato, MD,3 Bruno Lopes dos Santos Lobato, MD,1 Janari da Silva Pedroso, PhD,4 and Marco de Tubino Scanavino, MD, PhD5

ABSTRACT

Introduction: Sexual disorders are the most neglected nonmotor symptoms in Parkinson’s disease (PD). Although doctors seek greater priority to motor manifestations, which are the basis for the diagnosis of PD, the nonmotor symptoms deserve to be highlighted as much as the motor problems because of their strong presence and discomfort in the patients, causing the important impairment in the quality of life (QoL) of the individual with PD.

Aim: Provide the prevalence of sexual disorders among patients with PD and alert the medical profession to investigate and be familiar with problems related to QoL and sexual disorders in PD.

Methods: This is a large literature review on sexual disorders in PD and impaired QoL.

Main Outcome Measures: Sexual disorders in PD and prevalence between genders have been described in epidemiological studies. Neuroanatomy, pathophysiology, risk factors, QoL, and etiologies were reviewed.

Results: The estimate of the prevalence of sexual dysfunction in the form of compulsive sexual behavior in PD is higher in men by 5.2% than in women by 0.5%. This diagnosis is a determinant of intense and persistent suffering and is related to several health problems of a social, economic, personal, family, psychological, and occupational nature, which can even culminate in sexual abuse. It is most commonly associated with the use of drugs commonly used in PD therapy in 98.1% of cases. In addition to this serious public health problem, another common condition of sexual dysfunction occur with the decreased libido by loss of the neurotransmitter dopamine proper of the pathophysiology of PD.

Conclusion: The presence of sexual disorders in PD should be tracked and monitored because of its harmful consequences, whether due to increased sexual behavior or associated psychological distress, as well as the impacts on QoL. Early recognition and adequate treatment of PD in its fullness and richness of associated symptoms are essential for improving QoL. Santa Rosa Malcher CM, Roberto da Silva Gonçalves Oliveira K, Fernandes Caldato MC, et al. Sexual Disorders and Quality of Life in Parkinson’s Disease. Sex Med 2021;9:100280.

Copyright © 2020, The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Key Words: Compulsive Sexual Behavior; Hypersexuality; Sexual Disorders; Quality of Life; Parkinson’s Disease

INTRODUCTION

Regarding the variables that can affect the quality of life (QoL) and satisfaction of individuals with Parkinson’s disease (PD), sexual disorders assume their importance because they are of nonmotor symptoms (NMSs), those that stand out are the most neglected NMSs in this disease1–6 and that cause harm and distress in both men and women.1–6

According to the World Health Organization (WHO) (2006),7 sexual health is a fundamental aspect of life, regardless of the presence of sexual dysfunction, and each individual has the right to conduct their relationships and have personal control over sexual and reproductive behavior with adequate information and treatment. For that, specialists in movement disorders should periodically ask about the sexual life of their patients7 because an
active sexual life can bring benefits and be associated with better motor and nonmotor results, especially in men with early PD.9

More than 6 million people in the world have PD, a clinical syndrome diagnosed and most commonly known for motor signs characterized by bradykinesia, cogwheel stiffness, tremor at rest, and postural instability.10 As for sex, there is evidence of a higher risk of developing PD in men,11 and this reason, although unknown, may be related to the protection of estrogens in women.12–15 because the incidence of PD becomes similar between genders in women in postmenopausal.13,16 It is also noteworthy that age is the risk factor most correlated with PD,17 showing a greater appearance between 55 and 65 years in the advance of PD,18–20 the phase of life in which the individual wishes to feel productive but can be afflicted by great, economic,21 social, personal, family, psychological, and sexual suffering due to PD.22

There is a gap for the comprehensive literature review addressing all the sexual issues related to PD. We hypothesize that there are data from several aspects regarding sexual regulation issues. Our goal is to raise the data on sexual disorders related to PD. This review may provide critical information for the humanization of health care in PD, aiming care and attention to sexuality by health professionals.

METHODS

This literature review was based on the following key question: “What are the main points of sexual disorders that can be improved in PD for quality of life?”. Bibliographic searches by PubMed (2010–2020), Cochrane (May 2010–May 2020), and Google Scholar (2010–2020) with the following terms “Sexual disorders” and “Parkinson’s disease” resulted in 24, 40, and 17,800 articles, respectively. These searches also used the keywords “Sexual disorders” and “Parkinson” and resulted in 25, 41, and 20,000 articles, respectively. Only English texts were selected. Inclusion criteria were sexual dysfunction and the prevalence of PD between genders, neuroanatomy, pathophysiology, risk factors, and QoL. In the research, the terms were identified as the title and summary. After removing duplicates, all articles were evaluated according to the title, abstract, and text. Posters and abstracts from presentations at congresses or scientific meetings were included. First, 53 studies were included and reviewed. After searching the reference lists for these articles, another 18 studies were reviewed, resulting in a total of 71 articles.

RESULTS

In this article, we will focus on the lesser known aspects of PD about decreasing and increasing sexual behavior, physiology, associated risk factors, and clinical management.

Neuroanatomy and Sexuality Physiology

It is indisputable that the pathophysiology of PD is related to the degradation of the dopaminergic pathway,26–29 causing complex damage to sexual health related to sexual functioning and sexuality.2 Moreover, the neuroanatomy and physiology show differences and similarities between the sexes to determine sexual behaviors, and for good sexual functioning, the roles of the autonomous, sensory, and motor systems must be interconnected, with an intrinsic interdependence between the neurological, vascular, and endocrine systems. Thus, sexual desire depends, among others, on neurotransmitters, steroid hormones, vasoactive agents, and molecules that act through specific receptors, at the peripheral and cerebral levels.30 Chemoaffinities are also important to govern the rules of this game, contributing to sexual attraction and selection of partners. In addition, the genotype is responsible to promote the modulation of hormonal environment, as well the reproduction, and sexual behavior.31 On the other hand, also cultural32 and psychological factors can influence sexual desire33 and impact on the pituitary-gonadal axis.30 Figure 1.

Politis et al34 demonstrated to PD the increased sexual behavior related to greater activation in the limbic, paralimbic, temporal, occipital, somatosensory, and prefrontal cortex, related to emotional, cognitive, autonomic, visual, and motivational processes. In addition, increased sexual desire was also seen in the group using levodopa,34 although there are no significant increased levels of testosterone on the use of levodopa.35,36 It was observed that dopaminergic drugs may also enhance sexual responses, increasing oxytocin release from the paraventricular nucleus of the hypothalamus.37 In addition, the medial preoptic area of the hypothalamus is responsible for male sexual behavior.38

Regarding PD, low testosterone levels are involved with an increase in the progression of this disease39 and precocity,40 and also an advanced stage of the disease can lead to decreased sexual function.41 Moreover, testosterone plays an important role in the control of sexual desire mainly in men, with a decline after the age of 40 years and a decline of 1–2% per year.42 Low levels of testosterone can cause apathy, fatigue, changes in mood, loss of libido, and increased mortality, especially when related to increasing age.43 Physiologically, the testosterone levels decrease because of changes in the hypothalamic-pituitary axis, where the luteinizing hormonal pulses that induce testosterone production

Figure 1. The factors that influence the mechanism of sexual attraction are shown.
become more frequent, but to a lesser extent. But, a decrease in testosterone levels may also occur because of an increase in prolactin levels by comorbidities.

Prolactin is a hormone that stands out in men and women for controlling sexual desire, exerting an inhibitory action on sexual functions. In PD, due to the use of drug dopaminergic may occur the decreased secretion of prolactin, interfering with the inhibitory effect on sexual function and increasing sexual behavior. On the other hand, Nitkowska et al reported that in men with PD can be more susceptible to diseases if exposed to higher levels of prolactin and low levels of sex steroids, altering cognition, mood, and QoL. These changes in mental status can also influence sexual behavior in PD.

Regarding estrogens, these seem to be important in protecting women in PD because the greatest risk for developing PD is in men, presenting a risk similar in both sexes in the postmenopause. Estrogen acts as a neuroprotector in the nigrostriatal region of the brain avoiding the loss of dopaminergic neurons, increasing dopamine synthesis, and inhibiting its uptake, acting on the expression of dopamine receptors in the basal ganglia. In addition, estrogen is involved in female sexual desire.

Sexual Behavior in Parkinson’s Disease

In 2001, Basson introduced a new understanding of sexual response. Although Masters and Johnson, since 1966, adopted

| Study               | Population | Method                                                                                                                                           | Results                                                                 |
|---------------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Bronner et al       | 75 PD      | Cross-sectional study, U.K. brain bank criteria. Mini-Mental State Examination. Demographic and sexual function questionnaire. Israeli Sexual Behavior Inventory (ISBI). Hamilton depression rating scale | 46.9% of females had hypoactive sexual desire dysfunction.              |
| Azevedo et al       | 83 PD/69 GC| International Index of Erectile Function (IIFE). Sexual Functioning Index Feminine (IFSF). Beck Depression Index (BDI). Brief Symptom Inventory (BSI). Hoehn-Yahr scale | Was found a significant correlation to hypoactive sexual desire in women and men. |
| Sakakibara et al    | 115 PD/391 GC | Hoehn and Yahr scale. Magnetic resonance imaging. A nonstandardized instrument was used on pelvic organ function | 84% of women had hypoactive sexual desire dysfunction 83% of the men had hypoactive sexual desire disorder |
| Koller et al        | 50 PD      | The nonstandardized instrument was used                                                                                                           | 44% men and 62% of women had decreased sexual desire                    |
| Wermuth and Stenager | 25 PD    | Beck Depression Inventory (BDI) Hoehn-Yahr scale. Nonstandardized instrument was used                                                              | 27% men and 70% of women had decreased sexual desire                    |
| Kummer et al        | 90 PD      | Cross-sectional study. Beck Depression Inventory (BDI). Psychiatric interview (MINI-Plus). Unified Parkinson’s Disease Rating Scale (UPDRS). Hoehn-Yahr. Schwab—England Scale (SES). The Frontal Assessment Battery (FAB). Mini-Mental State Examination (MMSE). PD Fatigue Scale (PDFS) | The study showed that of loss of libido in men was 65.6% |

CG = control; group; PD = Parkinson’s disease.

Table 1. The main studies related to the development of sexual dysfunction in Parkinson’s disease with decreased libido, deficiency, or absence of desire for sexual activity

for men and women the sequence of the phases of arousal, plateau, orgasm, and resolution, Kaplan introduced the phase of desire, but, in turn, Basson found that for women, desire is not exactly necessary to initiate the “sexual response cycle.” However, other factors can act to start the cycle, such as greater affective proximity to the partner, bond, commitment, feeling attracted and attractive by the partner, and the investment to share and feel sexual pleasure. In the case of PD, it is common for these factors to be compromised, which can be directly or indirectly related to PD, and this influences sexual behavior. Azevedo et al made an important contribution demonstrating the reduction of sexual desire in PD in both sexes.

Thus, in general, sexual dysfunctions dialo
g with 2 main trends of alterations reported in patients with PD, which are the decrease but also the increase in sexual behaviors. These sexual problems can be treated effectively in most cases, requiring a better understanding of the personality style and risk factors to define the appropriate therapy. The nature of the disease, as well as the beginning, and progression must be registered, assessing the time of sexual activity and history before the onset of PD.

Epidemiological data show that the decrease in libido, deficiency, or lack of desire for sexual activity in women with PD ranges from 46.9 to 84%, as shown in Table 1, whereas difficulties in reaching orgasm occur in 75% of these patients.
It is also common to associate with depression, apathy, anxiety, difficulty with vaginal tightness or dryness vaginal, and involuntary urination. Although women with PD report less sexual desire, men with PD showed to have more sexual dysfunction and dissatisfaction with their sex life than women. On the other hand, the compulsive sexual behavior in PD presented a rate of 0.5% in women, which also should be given important attention.

The decrease in libido and deficiency or lack of desire for sexual activity in men with PD was between 27% and 83%, whereas the decrease in the penis erection and the inability to achieve or maintain sufficient penile erection for sexual intercourse is between 42.6% and 79%. The decrease in the latency time for ejaculation was 40.6%, whereas the decrease or absence of normal ejaculation was 79%, and the decrease in orgasm and the inability to reach orgasm was 87%.

### Table 2. The main studies on the most common risk factors related to the development of compulsive sexual behavior in Parkinson’s disease in men and women

| Risk factor | Study | Population | Location | Results |
|-------------|-------|------------|----------|---------|
| Gender      | Weintraub et al. | 3,090 PD | USA/Canada | CBS was found in 5.2% men and 0.5% in women |
|             | Voon et al. | 297 PD | Canada | The male gender was associated with CBS |
|             | Giladi et al. | 193 PD/190 CG | Israel | |
|             | Solla et al. | 349 PD | Italy | |
|             | Joutsa et al. | 575 PD | Finland | |
| Dopaminergic therapy | Fan et al. | 312 PD/132 CG | China | DA is associated with a higher risk of CSB |
|             | Pezzella et al. | 202 PD | Italy | DA can promote the development of CSB |
|             | Politis et al. | 12PD CSB/12PD without CSB | UK | |
|             | Weintraub et al. | 3,090 PD | USA/Canada | DA is associated with a higher risk of CSB |
|             | Uitti et al. | 13PD | USA | DA was associated with CSB. Levodopa monotherapy or associated with DA is a risk factor for CSB |
|             | Voon et al. | 297 PD | Canada | |
|             | Giladi et al. | 193 PD/190 CG | Israel | Longe treatment with DA can promote CSB |
|             | Ondo and Lai | 300 PD | USA | Increased sexual activity is common in the use of DA |
|             | Lee et al. | 1,167 PD | Korea | There is a significant correlation between CSB and the use of DA |
|             | Solla et al. | 349 PD | Italy | |
| Younger onset | Giladi et al. | 193 PD/190 CG | Israel | Younger age of PD motor symptom onset might be considered as a risk factor for the development of CSB |
|             | Sossi et al. | 27 PD/10 CG | Canada | Younger onset of PD has more motor and cognitive complications |
|             | Cooper et al. | 141 PD | USA | Younger age can be considered as a risk factor for CSB |
| Cognitive problems, history, and psychiatric damage | Voon et al. | 297 PD | Canada | CSB is associated with multiple psychiatric and cognitive damage |
|             | Joutsa et al. | 575 PD | Finland | CSB is associated with depression |
|             | Vitale et al. | 49 PD/14 CG | Italy | CSB is associated with prefrontal and memory damage |

CG = control group; CSB = compulsive sexual behavior; DA = dopamine agonist; PD = Parkinson’s disease.
About the phenomena of erectile and ejaculatory functions, the dopaminergic projections of the dorsal and posterior hypothalami are directed to the caudal thalamus and then to the spinal cord, which regulates erection and ejaculation; having a high density of dopaminergic receptors in the ischiocavernosus muscle, however, this system can be compromised in PD. On the other hand, regarding increased libido and sexual intercourse or forms of gratification outside the acceptance of social and personal limits, there was a rate of 5.2% in men, characterizing the compulsive sexual behavior.

The central dopaminergic pathways play an important role in man’s sexual function, increasing or decreasing libido and erectile activity, and the drug levodopa and dopaminergic agonists, which act in this pathway and facilitate ejaculation, compromised by the loss of the neurotransmitter dopamine. In men with PD, the feelings of the burden of sexual dysfunction are accompanied by fears, such as not meeting the expectations of their partners, thus avoiding sexual practices and causing thoughts of separation and withdrawal in the relationship. Other factors that may explain indirectly the reduction in sexual behavior in PD are related to the partners exercising the role of a caregiver and the difficulties increasing with the progression of the disease physically and mentally, with reduced attractiveness due to sloppy dressing, salivation, excessive sweating, abnormal movements such as tremors, and sleep disturbances, which can also result in the separation of the sleeping bed.

Compulsive Sexual Behavior

In 1970, compulsive sexual behavior in PD related to dopamine replacement therapy being associated mainly with the use of dopaminergic agonists, but also with high doses of levodopa was first described. In addition to compulsive sexual behavior, early PD with a history of psychiatry or cognitive impairment can exhibit a higher risk for men. The levodopa is the gold standard in initial PD therapy, having been used since 1960 and showing improvements in 80% of patients. However, some adverse reactions can occur over time; for example, in the case of compulsive consumption of the levodopa, the so-called dopaminergic dysregulation syndrome can lead to compulsive sexual behavior and other compulsions in up to 4% of patients. In turn, the chronic use of levodopa can develop dyskinesias and motor fluctuations, resulting in less sexual attraction between partners. These adverse reactions are iatrogenies that can affect physical, social, and occupational life. Such differences in response to medication between people and gender are probably controlled by the machinery of the dopamine genes.

In Brazil, epidemiological, behavioral, and clinical data related to sexual compulsiveness are very limited and more in PD where reports are scarce. However, this is a problem of serious proportions, which can impact on psychosocial, legal, and public health issues, leading to serious negative outcomes, such as social isolation, sexually transmitted infections, unemployment, divorce, financial problems, pregnancies unplanned, sexual harassment and abuse, and zoophilia.

The WHO was concerned with providing access to treatment and reducing stigma and shame in seeking help due to the compulsive sexual behavior and further promoting research and international attention to this serious health problem has recommended including the disorder of compulsive sexual behavior in the 11th edition of the International Classification of Diseases. The exacerbation of the compulsive sexual behavior can lead to remarkable suffering associated with the loss of the feeling of gratification and sexual satisfaction and failure to control intense sexual impulses, identified in a persistent and repetitive pattern, for a prolonged period of 6 months or more, leading to damage of personal life, family, education, and occupation and neglecting health, activities, and responsibilities. Recently, the debate between clinicians and researchers has been intensified in the last 20 years, with the compulsive sexual behavior assuming different names such as nymphomania, satyriasis, sexual addiction, even sexual behavior out of control, or hypersexuality. Although used synonymously, both the increased risk for compulsive sexual behavior and its outcome for hypersexuality disorder are complications of PD.

There is considerable frustration in the search for relief with sexual compulsion, similar to erectile dysfunction, limited performance sexual, and inability to achieve orgasm, raising concerns about failure and may lead to repeated attempts at sexual intercourse. Therapy for both partners and monitoring of problems involved must be alerted. In PD, the precise mechanism of compulsive sexual behavior is not clearly known, but both the dopaminergic and serotonergic pathways can contribute to the development and maintenance of compulsive sexual behavior and to the high level of anxiety in this disease. In addition, compulsive sexual behavior is commonly associated with depressed mood.

It is essential to warn about the risk of pathological behaviors and side effects of the medication, as patients may not be able to immediately report the symptoms they feel voluntarily. Thus, in PD, compulsive sexual behavior can be a challenge because there is no approved therapy, and the urgent first step is to reduce or discontinue the use of dopaminergic agonists. Other interventions are psychotherapy, antidepressants, multidisciplinary team approach, sex education, family planning, monitoring of human acquired immunodeficiency syndrome and other sexually transmitted infections and evaluation of medical problems. In a recent systematic review, naltrexone was used with promising results in compulsive sexual behavior refractory in PD, but further studies yet are needed with this drug to compulsive sexual behavior.

QoL and Sexual Differences in Parkinson’s Disease

Each individual has a perception of their health condition and how PD affects their QoL, so there is a need to formulate...
progression to limitations. For this, in PD, it is important to identify the factors that most compromise QoL, even if they are not the most well-known symptoms such as the motor, but they should be recognized briefly as NMSs being essential in the integral health assessment. In this case, NMSs may be present before or even after the diagnosis of PD and be prominent among the sexes as in the case of greater sexual dysfunction in men, where the hypersexuality disorder has been associated with decreased health and sexual satisfaction, and women in turn experience more psychological and social suffering.

Caregivers of patients with PD are also victims who are on the front lines to receive sexual assault in 26.9% of cases and physical aggression in 65.4%, as demonstrated in a palliative care clinic. Physical aggressions become more common in the advanced stage of the disease, whether due to cognitive decline, anxiety, depression, loss of autonomy, independence, and identity. In these circumstances, the emotional support must be constantly strengthened, to renegotiate the roles and suffering involved in the relationship, including those related to the effects of medication. Thus, patients using dopaminergic agonists have an increased risk of compulsive sexual behavior and should be warned about this risk that can occur at any time even after starting treatment.

Compulsive sexual behavior is considered an impulse control disorder and is mainly associated with PD with the use of dopaminergic agonists but also with high doses of levodopa in 98.1% of cases. Individuals treated with these drugs have a 1.7–3.5% risk of developing compulsive sexual behavior in PD, also varying from 2.2 to 8.3%. Using levodopa alone, the risk is 2.7% and using only dopaminergic agonists is 7.4%. Although compulsive sexual behavior in PD is not uncommon because of treatment with dopamine replacement and, especially in therapy with dopaminergic agonists, there is an underdiagnosis of this behavior in 27.3% of patients. This reveals that periodic screening and monitoring is necessary, also identifying other possible related risk factors such as male gender and being young, with early onset of PD and a history of behavioral problems, and the search for novelties, family history, and past history. In individuals diagnosed with PD younger than 60 years, possibly due to genetic factors or increased levodopa turnover, there is a greater risk of introducing dopamine agonists.

Regarding deficits in the executive function of human cognition, associated with compulsive sexual behavior, there is a loss of impulse control, loss of judgment and decision-making, emotional dysregulation with cognitive rigidity, and difficulties in sustained attention, and many of these domains may be affected. Behavioral changes can be observed as gambling, hyperphagia, abusive video game practices, obsessive shopping, aggression, long walks for many hours, repetitive behaviors called punding such as painting and gardening, or senseless tidiness and cleaning, organization, and fascination for word ordering and small collections of objects, with a variable prevalence of 1.4–14% in case of punding being many times non-diagnosed. Thus, the diagnosis of PD can have a great impact on QoL and patient satisfaction and can also affect the risk of mortality in the presence of NMSs and motor symptoms.

Therefore, it is vital to recognize that in PD, there are more than motor problems involved, but there are also serious issues affecting emotional, cognitive, and even social relationships. In addition, pharmacological therapy is important in the control of cognitive dysfunctions, and of mood disorders and impulse control disorders; such therapeutic targets are related to dopamine deficits and changes in serotoninergic, noradrenergic, and cholinergic systems in PD. Thus, there are still few individuals PD treated and identified for NMSs, although there is the possibility of treatment, and that is worrying because only treating motor signals is not sufficient.

Another important limitation of QoL in PD is related to pain, where these patients have a low pain threshold, which progresses during the development of the disease. The reduction of dopaminergic neurotransmission can compromise the body’s natural analgesic; this occurs by decreasing the activation of dopamine-mediated pain inhibitory pathways, which descend from the substantia nigra to the spinal cord and inhibit the transmission of upward nociceptive signals. Body discomfort is a relevant physical aspect of the disease, related to the loss of the pain domain, where women are commonly affected.

Although motor manifestations have more attention from doctors and patients and are the basis for the diagnosis of PD, NMSs deserve to be highlighted as much as motor problems because of their strong presence and discomfort in patients, causing impairment in QoL. In these damages caused by NMSs, 70% of individuals with PD have some neuropsychiatric disorder due to apathy, depression or anxiety. In addition, these individuals may also be affected by sensory problems, such as pain and hyposmia, sleep disorders, and problems in the autonomic nervous system, related to constipation, neurogenic bladder, orthostatic hypotension, erectile dysfunction, diaphoresis, salivation, and dysphagia.

In a way, although men are at a greater risk for compulsive sexual behavior and may experience impairment in cognition and communication, women have shown the greater risk for motor complications, postural instability, risks for tremor in early illness, compulsion for shopping and food, and less rigidity than men. Based on their activities of daily living, men and women have different expectations, and discrepant sexual needs can be observed in PD. Thus, in the PD approach, individuals should be contemplated as such in their achievements in treatment based on strategies that include personalized and diversified planning, identifying their...
goals, strengths, and weaknesses and the support where they are inserted.  

CONCLUSION

Sexual dysfunctions are marked problems in the lives of people with PD and are often neglected by health-care professionals. Symptoms may vary from an increase or decrease in sexual behaviors. The highest prevalence is in men, and the risk factors involved are the individual’s personality style and behavioral problems, the onset and progression of PD, the nature of the disease by its own physiology and genetics, the sexual history before and after the onset of PD, cultural and psychological factors involved, partners’ sexual needs and expectations, current or previous family history of impulse control disorders, and medications being used. Especially in this sense, drugs in the class of dopaminergic agonists are remarkable for being the ones that are most related to compulsive sexual behavior, with their use alone or associated with the drug levodopa. These findings indicate that sexual disorders in PD should be screened and monitored because of the natural history of the disease, resulting in loss of dopaminergic neurons and decreased libido and even because of their form of drug therapy, which can progress to compulsive sexual behaviors. Preventive measures for sexual dysfunctions should be instituted early, avoiding sexually transmitted infections, unwanted pregnancies, suffering, and social isolation and sexual abuse, among others, and thus providing the necessary individual, family, and community relief. Thus, sexual dysfunctions in PD are clinical conditions that must not be silenced and passed unseen and must participate in permanent planning. Owing to its multifactorial and multidimensional repercussions, PD may often need special care with a psychologist and/or doctor; for example, a psychiatrist, urologist, gynecologist, sexologist. Thus, although primary health care must be prepared for first care, it needs a strengthened support network for these patients. Integrity wished by the WHO is still a challenge. To overcome this fact, in addition to identifying the first manifestations of sexual dysfunction, the doctor must be willing to get involved beforehand, amplifying his view of the extended clinic to improve the QoL of the patient with PD in all its instances. For this, instead of focusing only on the motor symptoms related to the diagnosis of PD, the NMSs in which sexual disorders are part should be valued, as well as the aspects of promoting broad sexual health. For the future, more studies should be developed to evaluate the training and preparation of health professionals in the management of sexual disorders in PD.

Corresponding Author: Claudia Marques Santa Rosa Malcher, MD, Oncology and Medical Sciences Graduate Program, Federal University of Pará, Belém, Brazil. Tel: + 55 (91) 3205-9016; Fax: + 55 (91) 3205-9021; E-mail: claudiaufpa@gmail.com

Conflict of Interest: The authors report no conflicts of interest.

Funding: None.

STATEMENT OF AUTHORSHIP

C.M.S.R.M., M.T.S.: Conceptualization, Methodology, Writing - Review & Editing. B.L.S.L., J.S.P., K.R.S.G.O., M.C.F.C.: Writing - Review & Editing

REFERENCES

1. Basson R. Sexuality and Parkinson’s disease. Parkinsonism Relat Disord 1996;2:177-185.
2. Bhattacharyya KB, Miguel R. Sexual dysfunctions in Parkinson’s disease: an underrated problem in a much-discussed disorder. Int Rev Neurobiol 2017;134:859-876.
3. Gola M, Wordecha M, Marchewka A, et al. Visual sexual stimuli—cue or reward? A perspective for interpreting brain imaging findings on human sexual behaviors. Front Hum Neurosci 2016;10:402.
4. Gola M, Wordecha M, Sescousse G, et al. Can pornography be addictive? An fMRI study of men seeking treatment for problematic pornography use. Neuropsychopharmacology 2017;42:2021-2031.
5. Lewczuk K, Szmyd J, Skorko M, et al. Treatment seeking for problematic pornography use among women. J Behav Addict 2017;6:445-456.
6. Wordecha M, Wilk M, Kowalewska E, et al. “Pornographic binges” as a key characteristic of males seeking treatment for compulsive sexual behaviors: qualitative and quantitative 10-week-long diary assessment. J Behav Addict 2018;7:433-444.
7. World Health Organization. Defining sexual health: report of a technical consultation on sexual health, 28-31 January 2002. Geneva: WHO; 2006.
8. Moore O, Gurevich T, Korczyn A, et al. Quality of sexual life in Parkinson’s disease. Parkinsonism Relat Disord 2002;8:243-246.
9. Picillo M, Palladino R, Erro R, et al. The PRIAMO study: active sexual life is associated with better motor and non-motor outcomes in men with early Parkinson’s disease. Eur J Neurol 2019;26:1327-1333.
10. Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA 2020;323:548-560.
11. Pinares-Garcia P, Stratikopoulos M, Zagato A, et al. Sex: a significant risk factor for neurodevelopmental and neurodegenerative disorders. Brain Sci 2018;8:154.
12. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson’s disease: an exploratory case-control study. Mov Disord 2001;16:830-837.
13. Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2007;78:819-824.
14. Miller IN, Cronin-Golomb A. Gender differences in Parkinson’s disease: clinical characteristics and cognition. Mov Disord 2010;25:2695-2703.
15. Shulman LM. Gender differences in Parkinson’s disease. Gend Med 2007;4:8-18.
16. Nitkowska M, Czyżyk M, Friedman A. Reproductive life characteristics in females affected with Parkinson’s disease and in healthy control subjects—a comparative study on Polish population. *Neurolo Neurochir Pol* 2014;48:322-327.

17. Lang AE, Lozano AM. Parkinson’s disease. *N Engl J Med* 1988;339:1130-1143.

18. De Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. *Lancet Neurol* 2006;5:525-535.

19. De Rijk MD, Tzourio C, Breteler MM, et al. Prevalence of Parkinsonism and Parkinson’s disease in Europe: the EURO-PARKINSON Collaborative study. European community concerted action on the epidemiology of Parkinson’s disease. *J Neurol Neurosurg Psychiatry* 1997;62:10-15.

20. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson’s disease. *Mov Disord* 2003;18:19-31.

21. Fan W, Ding H, Ma J, et al. Impulse control disorders in Parkinson’s disease in a Chinese population. *Neurosci Lett* 2009;16-9.

22. Romana Pezzella F, Colosimo C, Vanacore N, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson’s disease. *Mov Disord* 2005;20:77-81.

23. Kummer A, Maia DP, Salgado JV, et al. Dopamine dysregulation syndrome in Parkinson’s disease: case report. *Arq Neuropsiquiatr* 2006;64:1019-1022.

24. O’sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome. *CNS Drugs* 2009;23:157-170.

25. Solla P, Bortolato M, Cannas A, et al. Paraphilias and paraphilic disorders in Parkinson’s disease: a systematic review of the literature. *Mov Disord* 2015;30:604-613.

26. Braak H, Braak E. Pathoanatomy of Parkinson’s disease. *J Neurol* 2000;247:ii3-iii10.

27. Braak H, Del Tredici K, Bratzke H, et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). *J Neurol* 2002;249:iii1-iii15.

28. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. *Neurobiol Aging* 2003;24:197-211.

29. Braak H, Ghebremedhin E, Rüb U, et al. Stages in the development of Parkinson’s disease-related pathology. *Cell Tissue Res* 2004;318:121-134.

30. Santi D, Spaggiari G, Gilioli L, et al. Molecular basis of androgen action on human sexual desire. *Mol Cell Endocrinol* 2018;467:31-41.

31. Gunst A, Jern P, Westberg L, et al. A study of possible associations between single nucleotide polymorphisms in the estrogen receptor 2 gene and female sexual desire. *J Sex Med* 2015;12:676-684.

32. Buhmann C, Dogac S, Vettorazzi E, et al. The impact of Parkinson disease on patients’ sexuality and relationship. *J Neural Transm* 2017;124:983-996.

33. Corona G, Rastrelli G, Ricca V, et al. Risk factors associated with primary and secondary reduced libido in male patients with sexual dysfunction. *J Sex Med* 2013;10:1074-1089.

34. Politis M, Loane C, Wu K, et al. Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson’s disease. *Brain* 2013;136:400-411.

35. Lundberg PO. Blood levels of FSH, LH, TSH, and GH in Parkinsonian patients before and during L-dopa treatment. *Acta Neurol Scand* 1972;48:427-432.

36. Sinhamahapatra SB, Kirschner MA. Effect of L-dopa on testosterone and luteinizing hormone production. *J Clin Endocrinol Metab* 1972;34:756-758.

37. Melis MR, Stancampiano R, Argiolas A. Hippocampal oxytocin mediates apomorphine-induced penile erection and yawning. *Pharmacol Biochem Behav* 1992;42:61-66.

38. Bronner G, Aharon-Peretz J, Hassin-Baer S. Sexuality in patients with Parkinson’s disease, Alzheimer’s disease, and other dementias. *Handb Clin Neurol* 2015;130:297-323.

39. Nitkowska M, Tomasiuk R, Czyżyk M, et al. Prolactin and sex hormones levels in males with Parkinson’s disease. *Acta Neurol Scand* 2015;131:411-416.

40. Okun MS, Wu SS, Jennings D, et al. Testosterone level and the effect of levodopa and agonists in early Parkinson disease: results from the INSPECT cohort. *J Clin Mov Disord* 2014;1:8.

41. Bronner G, Royter V, Korczyn AD, et al. Sexual dysfunction in Parkinson’s disease. *J Sex Marital Ther* 2004;30:95-105.

42. O’Donnell AB, Araujo AB, McKinlay JB. The health of normally aging men: the Massachusetts male aging study (1987–2004). *Exp Gerontol* 2004;39:975-984.

43. Decaroli MC, Rochira V. Aging and sex hormones in males. *Virulence* 2017;8:545-570.

44. Carter JN, Tyson JE, Tous C, et al. Prolactin-secreting tumors and hypogonadism in 22 men. *N Engl J Med* 1978;299:847-852.

45. Uitti RJ, Tanner CM, Rajput AH, et al. Hypersexuality with antiparkinsonian therapy. *Clin Neuropsychol* 1989;12:375-383.

46. Atagün M, Atmaca B, Özer F, et al. Determinants of sexual dysfunction in male and female patients with Parkinson’s disease. *Dusunen Adam J Psychiatry Neurol Sci* 2013;26:1.

47. Basson R. Human sex-response cycles. *J Sex Marital Ther* 2001;27:33-43.

48. Masters WH, Johnson VE. Human sexual response. Boston: Little, Brown and Company; 1966.

49. Kaplan HS. Hypoactive sexual desire. *J Sex Marital Ther* 1977;3:3-9.

50. Azevedo J, Esteves M, Rosas MJ, et al. Disfunção sexual na Doença de Parkinson. *Arq Neurol* 2010;24:39-45.

51. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. *Arch Neurol* 2010;67:589-595.

52. Basson R, Bronner G. Management and rehabilitation of neurologic patients with sexual dysfunction. *Handb Clin Neurol* 2015;130:415-434.

53. Lundberg PO. Approach to the male patient with sexual dysfunction. *Handb Clin Neurol* 2015;130:137-142.
54. Sachdeva J, Harbishettar V, Baraclough M, et al. Clinical profile of compulsive sexual behaviour and paraphilia in Parkinson’s disease. J Parkinsons Dis 2014;4:665-670.

55. Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci 2001;92:76-85.

56. Koller WC, Vetere-Overfield B, Williamson A, et al. Sexual dysfunction in Parkinson’s disease. Clin Neuropharmacol 1990;13:461-463.

57. Wermuth L, Stenager E. Sexual problems in young patients with Parkinson’s disease. Acta Neurol Scand 1995;91:453-455.

58. Clayton AH, El Haddad S, Iluonakhamhe JP. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opin Drug Saf 2014;13:1361-1374.

59. Broto L, Atallah S, Johnson-Agbakwu C, et al. Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med 2016;13:538-571.

60. Welsh M, Hung L, Waters CH, et al. Sexuality in women with Parkinson’s disease. Mov Disord 1997;12:923-927.

61. Kummer A, Cardoso F, Teixeira AL. Loss of libido in Parkinson disease. J Neurol Transm 2009;6:1024-1031.

62. Bronner G, Hassin-Baer S, Gurevich T. Sexual preoccupation behavior in Parkinson’s disease. J Parkinsons Dis 2017;7:175-182.

63. Giuliano F, Allard J. Dopamine and sexual function. Int J Impot Res 2001;13:518-528.

64. Ahlenius S, Engel J, Larsson K, et al. Effects of pergolide and bromocriptine on male rat sexual behavior. J Pharmacol 1982;54:165-170.

65. Barbeau A, Roy M. Six-year results of treatment with levodopa plus benzerazide in Parkinson’s disease. Neurology 1976;26:399.

66. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006;67:1254-1257.

67. Giladi N, Weitzman N, Schreiber S, et al. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson’s disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol 2007;21:501-506.

68. Ondo WG, Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord 2008;14:28-32.

69. Lee JY, Kim JM, Kim JW, et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 2010;16:202-207.

70. Solla PAOLO, Cannas A, Floris GL, et al. Behavioral, neuropsychiatric and cognitive disorders in Parkinson’s disease patients with and without motor complications. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1009-1013.

71. Joutsa J, Martikainen K, Vahlberg T, et al. Impulse control disorders and depression in Finnish patients with Parkinson’s disease. Parkinsonism Relat Disord 2012;18:155-160.

72. Sossi V, de la Fuente-Fernández R, Schulzer M, et al. Age-related differences in levodopa dynamics in Parkinson’s: implications for motor complications. Brain 2006;129:1050-1058.

73. Cooper CA, Jadidian A, Paggi M, et al. Prevalence of hypersexual behavior in Parkinson’s disease patients: not restricted to males and dopamine agonist use. Int J Gen Med 2009;2:57.

74. Vitale C, Santangelo G, Trojano L, et al. Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson’s disease. Mov Disord 2011;26:830-836.

75. Tambsasco N, Romoli M, Calabresi P. Levodopa in Parkinson’s disease: current status and future developments. Curr Neuropharmacol 2018;16:1239-1252.

76. Hughes AJ, Daniel SE, Blankson S, et al. A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 1993;50:140-148.

77. Giovannoni G, O’Sullivan JD, Turner K, et al. Hedonistic, homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-428.

78. Obeso JA, Olanow CW, Nutt JC. Levodopa motor complications in Parkinson’s disease. Trends Neurosci 2000;52:57.

79. Scanavino MDT, Ventuneac A, Rendina HJ, et al. Sexual compulsivity scale, compulsive sexual behavior inventory, and hypersexual disorder screening inventory: translation, adaptation, and validation for use in Brazil. Arch Sex Behav 2016;45:207-217.

80. Kuzma JM, Black DW. Epidemiology, prevalence, and natural history of compulsive sexual behavior. Psychiatr Clin North Am 2008;31:603-611.

81. World Health Organization. International classification of diseases for mortality and morbidity statistics. 11th revision; Available at: https://icd.who.int/browse11/l-m/en. Accessed May 20, 2020.

82. Gola M, Potenza MN. Promoting educational, classification, treatment, and policy initiatives. J Behav Addict 2018;7:208-210.

83. Kraus SW, Krueger RB, Brien P, et al. Compulsive sexual behaviour disorder in the ICD-11. World Psychiatry 2018;17:109-110.

84. Reed GM, First MB, Kogan CS, et al. Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. World Psychiatry 2019;18:3-19.

85. Kowalewska E, Grubbs JB, Potenza MN, et al. Neurocognitive mechanisms in compulsive sexual behavior disorder. Curr Sex Health Rep 2018;10:255-264.

86. Verholleman A, Victorri-Vigneau C, Laforgue E, et al. Naltrexone use in treating hypersexuality induced by dopamine replacement therapy: impact of OPRM1 A/G polymorphism on its effectiveness. Int J Mol Sci 2020;21:3002.
87. Bancroft J, Vukadinovic Z. Sexual addiction, sexual compulsivity, sexual impulsivity, or what? Toward a theoretical model. *J Sex Res* 2004;41:225-234.

88. Kaplan MS, Krueger RB. Diagnosis, assessment, and treatment of hypersexuality. *J Sex Res* 2010;47:181-198.

89. Bronner G, Vodušek DB. Management of sexual dysfunction in Parkinson's disease. *Ther Adv Neurol Disord* 2011;4:375-383.

90. Nakum S, Cavanna AE. The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: a systematic literature review. *Parkinsonism Relat Disord* 2016;25:10-16.

91. Codling D, Shaw P, David AS. Hypersexuality in Parkinson's disease: systematic review and report of 7 new cases. *Mov Disord Clin Pract* 2015;2:116-126.

92. Nair D, Pawar A, Kalra G, et al. An Indian study of hypersexual disorder in patients with anxiety and mood disorders. *Sex Addict Compulsivity* 2013;20:292-305.

93. Baumann-Vogel H, Valko PO, Eisele G, et al. Impulse control disorders in Parkinson's disease: don't set your mind at rest by self-assessments. *Eur J Neurol* 2015;22:603-609.

94. Bucks RS, Cruise KE, Skinner TC, et al. Coping processes and health-related quality of life in Parkinson's disease. *Int J Geriatr Psychiatry* 2011;26:247-255.

95. Maes S, Leventhal H, de Ridder DT. Coping with chronic diseases. *Handbook of coping: theory, research, applications; 1996. p. 221-251.*

96. Carod-Artal FJ, Vargas AP, Martinez-Martin P. Determinants of quality of life in Brazilian patients with Parkinson's disease. *Mov Disord* 2007;22:1408-1415.

97. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. *Mov Disord* 2011;26:399-406.

98. Reich SG, Savitt JM. Parkinson's disease. *Med Clin North Am* 2019;103:337-350.

99. Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson disease. *CMAJ* 2016;188:1157-1165.

100. Liu R, Umbach DM, Peddada SD, et al. Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease. *Neurology* 2015;84:2107-2115.

101. Picillo M, Amboni M, Erro R, et al. Gender differences in nonmotor symptoms in early, drug naïve Parkinson's men. *J Neurol* 2013;260:2849-2855.

102. Szewczyk-Krolikowski K, Tomlinson P, Nithi K, et al. The influence of age and gender on motor and non-motor features of early Parkinson's disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. *Parkinsonism Relat Disord* 2014;20:99-105.

103. Långström N, Hanson RK. High rates of sexual behavior in the general population: correlates and predictors. *Arch Sex Behav* 2006;35:37-52.

104. McBride KR, Reece M, Sanders SA. Using the sexual compulsivity scale to predict outcomes of sexual behavior in young adults. *Sex Addict Compulsivity* 2008;15:97-115.

105. Bruno V, Mancini D, Ghoche R, et al. High prevalence of physical and sexual aggression to caregivers in advanced Parkinson’s disease. Experience in the palliative care program. *Parkinsonism Relat Disord* 2016;24:141-142.

106. Ceravolo R, Frosini D, Rossi C, et al. Impulse control disorders in Parkinson’s disease: definition, epidemiology, risk factors, neurobiology and management. *Parkinsonism Relat Disord* 2009;15:S111-S115.

107. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. *JAMA* 2014;311:1670-1683.

108. Grant JE, Atnaca M, Fineberg NA, et al. Impulse control disorders and “behavioural addictions” in the ICD-11. *World Psychiatry* 2014;13:125-127.

109. Barbosa PM, Gripe T, Lees AJ, et al. Compulsive sexual behaviour in Parkinson's disease is associated with higher doses of levodopa. *J Neurol Neurosurg Psychiatry* 2018;89:1121-1123.

110. Munhoz RP, Fabiani G, Becker N, et al. Increased frequency and range of sexual behavior in a patient with Parkinson's disease after use of pramipexole: a case report. *J Sex Med* 2009;6:1177-1180.

111. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. *Arch Neurol* 2006;63:969-973.

112. Latourelle JC, Beste MT, Hadzi TC, et al. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson’s disease: a longitudinal cohort study and validation. *Lancet Neurol* 2017;16:908-916.

113. Smith KM, Xie SX, Weintraub D. Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. *J Neurol Neurosurg Psychiatry* 2016;87:864-870.

114. Voon V, Napier TC, Frank MJ, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson’s disease: an update. *Lancet Neurol* 2017;16:238-250.

115. Warren OC, Kieburzt K, Rascal O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. *Mov Disord* 2013;28:1064-1071.

116. Reid RC, Garos S, Carpenter BN, et al. A surprising finding related to executive control in a patient sample of hypersexual men. *J Sex Med* 2011;8:2227-2236.

117. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. *Mov Disord* 2004;19:397-405.

118. Miyasaki JM, Al Hassan K, Lang AE, et al. Punding prevalence in Parkinson's disease. *Mov Disord* 2007;22:1179-1181.

119. Voon V, Fernagut PO, Wickens J, et al. Chronic dopaminergic stimulation in Parkinson’s disease: from dyskinesias to impulse control disorders. *Lancet Neurol* 2009;8:1140-1149.

120. Buczak-Stec EW, König HH, Hajek A. Impact of incident Parkinson’s disease on satisfaction with life. *Front Neurol* 2018;9:589.
Sexual Disorders in Parkinson’s Disease

121. de Lau LM, Verbaan D, van Rooden SM, et al. Relation of clinical subtypes in Parkinson’s disease with survival. Mov Disord 2014;29:150-151.

122. Stucki G, Cieza A, Melvin J. The international classification of functioning, disability and health: a unifying model for the conceptual description of the rehabilitation strategy. J Rehabil Med 2007;39:279-285.

123. Kim HJ, Jeon BS, Paek SH. Nonmotor symptoms and subthalamic deep brain stimulation in Parkinson’s disease. J Mov Disord 2015;8:83.

124. Hemmerle AM, Herman JP, Seroogy KB. Stress, depression and Parkinson’s disease. Exp Neurol 2012;233:79-86.

125. Titova N, Qamar MA, Chaudhuri KR. The nonmotor features of Parkinson’s disease. Int Rev Neurobiol 2017;132:33-54.

126. Ba F, Obaid M, Wieler M, et al. Parkinson disease: the relationship between non-motor symptoms and motor phenotype. Can J Neurol Sci 2016;43:261-267.

127. Cury RG, Galhardoni R, Fonoff ET, et al. Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms. Eur J Pain 2016;20:151-165.

128. Djaldetti R, Shifrin A, Rogowski Z, et al. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology 2004;62:2171-2175.

129. Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, et al. Levodopa raises objective pain threshold in Parkinson’s disease: a RIII reflex study. J Neurol Neurosurg Psychiatry 2007;78:1140-1142.

130. Lim SY, Farrell MJ, Gibson SJ, et al. Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson’s disease? Mov Disord 2008;23:1689-1695.

131. Marsala SZ, Tinazzi M, Vitaliani R, et al. Spontaneous pain, pain threshold, and pain tolerance in Parkinson’s disease. J Neurol 2011;258:627-633.

132. Fil A, Cano-de-la-Cuerda R, Muñoz-Hellín E, et al. Pain in Parkinson disease: a review of the literature. Parkinsonism Relat Disord 2013;19:285-294.

133. Tedrus GMAS, Fonseca LC, Kange PM. Parkinson’s disease: impact of clinical and cognitive aspects on quality of life. Demen Neuropsychol 2010;4:131-137.

134. Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 2009;24:1641-1649.

135. Beiske AG, Loge JH, Hjermstad MJ, et al. Fatigue in Parkinson’s disease: prevalence and associated factors. Mov Disord 2010;25:2456-2460.

136. Scott B, Borgman A, Engler H, et al. Gender differences in Parkinson’s disease symptom profile. Acta Neurol Scand 2000;102:37-43.

137. Santos-García D, de la Fuente-Fernández R. Impact of nonmotor symptoms on health-related and perceived quality of life in Parkinson’s disease. J Neurol Sci 2013;332:136-140.

138. Jordan LL, Zahodne LB, Okun MS, et al. Hedonic and behavioral deficits associated with apathy in Parkinson’s disease: potential treatment implications. Mov Disord 2013;28:1301-1304.

139. Wen MC, Chan LL, Tan LCS, et al. Depression, anxiety, and apathy in Parkinson’s disease: insights from neuroimaging studies. Eur J Neurol 2016;23:1001-1019.

140. Weintraub D, David AS, Evans AH, et al. Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord 2015;30:121-127.

141. Lubomski M, Rushworth RL, Lee W, et al. Sex differences in Parkinson’s disease. J Clin Neurosci 2014;21:1503-1506.

142. Prange S, Danaila T, Laurencin C, et al. Age and time course of long-term motor and nonmotor complications in Parkinson disease. Neurology 2019;92:e148-e160.

143. Gao X, O’Reilly ÉJ, Schwarzschild MA, et al. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology 2016;86:520-526.

144. Savica R, Grossardt BR, Bower JH, et al. Risk factors for Parkinson’s disease may differ in men and women: an exploratory study. Horm Behav 2013;63:308-314.

145. Koran LM, Faber RJ, Aboujaoude E, et al. Estimated prevalence of compulsive buying behavior in the United States. Am J Psychiatry 2006;163:1806-1812.

146. Striegel-Moore RH, Franko DL. Epidemiology of binge eating disorder. Int J Eat Disord 2003;34:519-529.

147. Baba Y, Putzke JD, Whaley NR, et al. Gender and the Parkinson’s disease phenotype. J Neurol 2005;252:1201-1205.

148. Georgiev D, Hamberg K, Hariz M, et al. Gender differences in Parkinson’s disease: a clinical perspective. Acta Neurol Scand 2017;136:570-584.